|
A trial of a newly approved breast cancer drug in patients who are not typically targeted by the drug resulted in extremely encouraging results never seen before. Patients who received the drug survived longer and had lower growth in their tumours than those who received standard chemotherapy. ThePrint’s Sandhya Ramesh explains the findings.
Brought to by @Kia India
To know more, read: https://theprint.in/health/experimental-drug-shows-success-in-advanced-breast-cancer-patients-better-than-standard-chemo/995701/ Subscribe to the Pure Science Telegram Channel https://t.me/PureScienceWithSandhyaRamesh
Supplementary reading: Modi, S., et al.; The New England Journal of Medicine (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2203690 |
.png)
More
Religion & Spirituality
Education
Arts and Design
Health
Fashion & Beauty
Government & Organizations
Kids & family
Music
News & Politics
Science & Medicine
Society & Culture
Sports & Recreation
TV & Film
Technology
Philosophy
Storytelling
Horror and Paranomal
True Crime
Leisure
Travel
Fiction
Crypto
Marketing
History
Comedy
Arts
Games & Hobbies
Business
Motivation